Navigation Links
Investigational eye treatment: Corneal collagen crosslinking research study
Date:9/20/2010

Teaneck, NJ The Cornea and Laser Eye Institute, with Principal Investigator, Peter S. Hersh M.D., is conducting a research study to study the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia.

Keratoconus is a disease of the cornea, the clear front lens of the eye (like the crystal on a watch), that occurs in the overall population at a rate of about one in 2000. It usually begins in the teens and 20's and can worsen over time. It is often discovered when vision cannot be properly corrected with glasses. Keratoconus results in thinning of the corneal tissues. Consequently, the cornea bulges out of its smooth, clear, dome-like structure, and assumes a more conical and irregular configuration. Because of this change in shape, the cornea loses its ability to form a clear image in the eye and the patient's vision can decrease drastically. Treatments include specialty keratoconus contact lenses and corneal inlays. However, the keratoconus cornea can continue to bulge over time and some keratoconus patients ultimately may require corneal transplantation to regain vision.

Corneal collagen crosslinking (CXL) using ultraviolet light combined with riboflavin (Vitamin B2) is an investigational procedure designed to strengthen the cornea and decrease the progression of keratoconus. CXL is an investigational procedure and is not approved for use in the United States. However, here at the CLEI Center for Keratoconus, we are participating in a research study of CXL. The goal of the study is to assess the safety and efficacy of crosslinking for the treatment of keratoconus as well as corneal ectasia after LASIK. If successful, CXL may decrease progression of keratoconus and maintain the patient's vision over time.

During the crosslinking procedure, anesthesia drops are administered. The surface epithelial cells of the cornea are then removed and riboflavin drops are administered for 30 minutes. The riboflavin acts both to enhance the crosslinking effect and to protect the rest of the eye from the UV exposure.

The patient then looks at a UV emitting light for 30 minutes. At the conclusion of the procedure, a soft contact lens bandage is applied. The contact lens is left in place to improve healing for approximately 5 days and is then removed. Antibiotic and anti-inflammatory drops are used for two weeks afterwards.


'/>"/>

Contact: Stacey Lazar
slazar@vision-institute.com
201-883-0505
The Cornea and Laser Eye Institute, P.A.
Source:Eurekalert

Related medicine news :

1. New investigational compound targets pancreatic cancer cells
2. Pivotal data for the investigational treatment PSD502 for primary premature ejaculation
3. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
4. Study finds new key to corneal transplant success
5. Khanna Institute to Provide Intacs Corneal Implants in Beverly Hills
6. Corneal Transplant Not Hurt by Long Preservation Time
7. Collagen manufactured from transgenic tobacco plants at Hebrew University
8. Hard to Treat Diseases (HTDS) Collagenna Skin Care Business Model and Chilean Update
9. Drug to treat alcoholism goal of UH professors research
10. Mayo-led researchers discover genetic variants modifying breast cancer risk
11. Rutgers researchers discover how HIV resists AZT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, ... Along with his wonderful accolades and stellar patient reviews, Dr. Batelli continues to ... , Dr. Eugene Batelli is a highly trained Podiatric Surgeon who specializes in ...
(Date:5/26/2016)... Pass, OR (PRWEB) , ... May 26, 2016 , ... ... of Bio-Logic Aqua® Research Water Life Science® and international water advocate, was honored by ... of the women in ancient Egypt who knelt on the banks of the Nile ...
(Date:5/26/2016)... Columbus, Ohio (PRWEB) , ... May 26, 2016 ... ... thought leader Mike Morrow-Fox . With over 20 years of experience in ... organizations, as well as several years of university teaching, Morrow-Fox will be featured ...
(Date:5/26/2016)... CT; Scottsdale, AZ (PRWEB) , ... ... ... insights consultancy, Actûrus , is happy to announce the launch of ... thinking of the funnel model to reflect the dynamic landscape of modern ...
(Date:5/26/2016)... ... May 26, 2016 , ... In Madeira Beach Florida, a small town ... drawbridge, citizens formed an organization, Madeira Beach United, to oppose two development projects undertaken ... town center to a high rise urban environment. , According to the Tampa ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... HONG KONG , May 24, 2016 /PRNewswire/ ... primer stent de doble terapia del mundo, introduce ... fístula arteriovenosa. OrbusNeich, una compañía global ... cambian las vidas, ha expandido su cartera incluyendo ... catéteres balón JADE™ y Scoreflex™ PTA son los ...
(Date:5/24/2016)... -- Een app die artsen over de ... kunnen behandelen, hun kennis kunnen delen en van elkaar ... en revolutionaire MDLinking App, ontwikkeld door een internationale groep ... Flu en oncologisch chirurg dr. Gijs van Acker ... op dinsdag 24 mei officieel gepresenteerd op het Amsterdam ...
(Date:5/23/2016)... May 23, 2016 Transparency Market ... Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, ... According to the report, the exocrine pancreatic insufficiency market ... from 2015 to 2023 to reach US$2.85 Bn by ... condition characterized by the deficiency of the exocrine pancreatic ...
Breaking Medicine Technology: